Alliance Global Partners Initiates Coverage on MediWound (NASDAQ:MDWD)

Alliance Global Partners began coverage on shares of MediWound (NASDAQ:MDWD - Free Report) in a research report released on Friday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $25.00 price objective on the biopharmaceutical company's stock.

Other equities analysts have also recently issued reports about the company. Craig Hallum initiated coverage on MediWound in a report on Friday, February 28th. They set a "buy" rating and a $39.00 target price for the company. StockNews.com raised shares of MediWound to a "sell" rating in a research report on Friday, March 21st. Finally, HC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of MediWound in a report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat, MediWound presently has an average rating of "Moderate Buy" and a consensus target price of $29.75.

MediWound Stock Up 0.8 %

MDWD traded up $0.14 during trading on Friday, reaching $17.93. The company had a trading volume of 11,750 shares, compared to its average volume of 88,067. The stock has a market cap of $193.73 million, a P/E ratio of -6.18 and a beta of 0.30. MediWound has a 52 week low of $12.78 and a 52 week high of $24.00. The business has a 50 day simple moving average of $16.93 and a 200-day simple moving average of $17.46.

MediWound (NASDAQ:MDWD - Get Free Report) last announced its earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.23. The company had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.79 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter last year, the firm posted ($0.19) earnings per share. As a group, equities research analysts expect that MediWound will post -2.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. ARK Investment Management LLC raised its stake in MediWound by 6.7% during the first quarter. ARK Investment Management LLC now owns 106,930 shares of the biopharmaceutical company's stock worth $1,660,000 after acquiring an additional 6,684 shares during the period. Bank of New York Mellon Corp grew its stake in shares of MediWound by 14.8% in the 1st quarter. Bank of New York Mellon Corp now owns 18,357 shares of the biopharmaceutical company's stock worth $285,000 after purchasing an additional 2,370 shares during the last quarter. Yelin Lapidot Holdings Management Ltd. raised its position in shares of MediWound by 0.8% during the first quarter. Yelin Lapidot Holdings Management Ltd. now owns 858,000 shares of the biopharmaceutical company's stock worth $13,316,000 after purchasing an additional 6,639 shares during the period. Silverberg Bernstein Capital Management LLC raised its holdings in shares of MediWound by 13.1% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 103,944 shares of the biopharmaceutical company's stock valued at $1,613,000 after acquiring an additional 12,060 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of MediWound by 1,507.1% in the first quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 1,703 shares during the period. Hedge funds and other institutional investors own 46.83% of the company's stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.